NTLA
Intellia Therapeutics Inc
12.30$
+1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +668.1% | +264.0% | +25.8% | -7.7% | -3.8% | +102.3% | +91.4% | +17.4% | -14.4% | -8.5% | -29.3% | |
| – | +666.3% | +262.4% | +26.1% | -8.4% | -10.9% | +113.0% | +24.8% | +58.2% | -18.0% | -35.9% | -17.5% | |
| – | +670.1% | +260.2% | +24.8% | -82.7% | -2.8% | +179.6% | -22.9% | +324.2% | -56.7% | -16.6% | -17.8% | |
| – | +670.1% | +260.2% | +24.8% | -7.8% | -10.9% | +113.6% | +25.3% | +59.3% | -23.5% | -34.1% | -25.2% | |
| – | – | +545.4% | +62.2% | -27.9% | -38.8% | -53.9% | -4.6% | +85.5% | +867.5% | -76.6% | +11.2% | |
| – | – | – | +0.0% | +0.0% | +0.0% | -1,914,600,100.0% | – | – | – | – | – | |
| – | +779.2% | +292.5% | +43.7% | +11.7% | +117.6% | -57.1% | +31.5% | +33.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +372.6% | +502.9% | -15.1% | -8.3% | -7.2% | +131.8% | +70.3% | +11.9% | -11.9% | +27.2% | -46.5% | |
| – | +354.1% | +187.3% | +2.0% | +29.4% | -12.2% | +80.3% | +95.8% | +0.6% | -9.0% | -3.8% | -6.3% | |
| – | – | – | – | – | – | -0.9% | +60.0% | +83.1% | +11.5% | +8.9% | +30.8% | |
| – | +583.4% | +242.1% | -53.3% | +24.7% | +45.5% | +165.4% | -7.7% | -46.6% | +44.6% | +95.8% | +38.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +790.2% | +211.5% | +43.3% | -7.5% | -2.9% | +95.3% | +97.4% | +18.8% | -15.0% | -17.0% | -23.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +71.7% | +96.0% | +4.0% | +19.6% | +9.7% | +18.5% | +26.6% | +8.6% | +15.3% | +11.4% | +9.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.